Recently, a variety of novel biomarkers such as PITX2 methylation and C1GALT1 autoantibody that forecast prognosis, and B7-H3 that predicts immunotherapeutic prognosis and reaction in HNSCC were identified gradually [37–39]. The gene discussed is CD276; the disease is head and neck squamous cell carcinoma.